History | Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | Guidance | NICE

History

A list of downloadable documents created during development.

Expected publication

Equality Impact Assessment (Guidance development) ^{PDF 305 KB} 29 March 2017

Final appraisal determination

Final appraisal determination
Final appraisal determination document ^{PDF 152 KB} 02 March 2017
Committee papers ^{PDF 6.48 MB} 02 March 2017
Public committee slides ^{PDF 648 KB} 02 March 2017

Draft guidance: 1

Draft guidance: 1
Appraisal consultation document ^{PDF 226 KB} 17 November 2015
Committee papers ^{PDF 8.36 MB} 17 November 2015

Assessment report

Assessment report ^{PDF 4.52 MB} 01 September 2015

Final scope

Final scope ^{PDF 40 KB} 23 March 2015

Final matrix

Final matrix ^{PDF 51 KB} 23 March 2015

Comments table

Comments table ^{PDF 56 KB} 23 March 2015

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): final protocol

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): final protocol ^{PDF 139 KB} 09 February 2015

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): equality impact assessment scoping

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): equality impact assessment scoping ^{PDF 14 KB} 01 December 2014

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): provisional matrix

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): provisional matrix ^{PDF 35 KB} 26 September 2014

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): draft scope

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): draft scope ^{PDF 38 KB} 26 September 2014